Pseudoginsenoside-F11 promotes functional recovery after transient cerebral ischemia by regulating the microglia/macrophage polarization in rats

Int Immunopharmacol. 2021 Oct:99:107896. doi: 10.1016/j.intimp.2021.107896. Epub 2021 Jul 7.

Abstract

The polarization of microglia/macrophages after cerebral ischemia is critical for post-stroke damage/recovery. Previously, we found that pseudoginsenoside-F11 (PF11), an ocotillol-type saponin, has neuroprotective effects on permanent and transient cerebral ischemia in rats. This study aimed to investigate the effects and potential mechanisms of PF11 on microglia/macrophage polarization following transient cerebral ischemia in rats. In vivo data showed that oral administration of PF11 (12 mg/kg) significantly attenuated cognitive deficits and sensorimotor dysfunction, infarct volume and brain edema in transient middle cerebral artery occlusion (tMCAO)-treated rats, as well as reduced the loss of neurons and the over-activation of microglia in penumbra of ipsilateral striatum and cortex. Notably, the proportion of M2 microglia/macrophages in the total activated microglia/macrophages peaked on day 14 after tMCAO in rats, while PF11 promoted its peak advancing to day 3 post-tMCAO, which allowing the damaged brain to enter the repair period more quickly. Furthermore, PF11 increased the expression of anti-inflammatory markers and decreased the expression of pro-inflammatory markers in ipsilateral striatum and cortex. In addition, in vitro data showed that PF11 inhibited the induction of M1 microglia by oxygen glucose deprivation/re-oxygenation (OGD/R)-induced neurons, and promoted the polarization of microglia to M2 phenotype in a Jumonji domain-containing protein 3 (Jmjd3)-dependent manner. Moreover, PF11 promoted the protection of M2 microglia and attenuated the exacerbation of M1 microglia on OGD/R-induced neuronal damage. Taken together, these results indicate that PF11 protects ischemic neurons by promoting M2 microglia/macrophage polarization in a Jmjd3-dependent manner, ultimately facilitating the functional recovery following transient cerebral ischemia.

Keywords: Jumonji domain-containing protein 3; Microglia/macrophage polarization; Oxygen glucosedeprivation/re-oxygenation; Pseudoginsenoside-F11; Transient cerebral ischemia.

MeSH terms

  • Animals
  • Brain / drug effects
  • Brain / immunology
  • Cell Hypoxia / drug effects
  • Cells, Cultured
  • Cytokines / genetics
  • Ginsenosides / pharmacology
  • Ginsenosides / therapeutic use*
  • Glucose / deficiency
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Infarction, Middle Cerebral Artery / genetics
  • Infarction, Middle Cerebral Artery / immunology
  • Ischemic Attack, Transient / drug therapy*
  • Ischemic Attack, Transient / genetics
  • Ischemic Attack, Transient / immunology
  • Jumonji Domain-Containing Histone Demethylases / genetics
  • Macrophages / cytology
  • Macrophages / drug effects
  • Male
  • Microglia / cytology
  • Microglia / drug effects
  • Neurons / drug effects
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Cytokines
  • Ginsenosides
  • Neuroprotective Agents
  • pseudoginsenoside F11
  • Jumonji Domain-Containing Histone Demethylases
  • Kdm6b protein, rat
  • Glucose